Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics
Rznomics will gain access to Lilly’s lab space and research support as it works to speed development of RNA-based gene therapies.
- On Monday, August 24, 2026, South Korea-based Rznomics Inc. announced it is joining Lilly Gateway Labs in San Diego, California, to advance its RNA-based gene therapy development.
- By joining Lilly Gateway Labs, Rznomics gains access to strategic capital, specialized wet lab facilities, and technology platforms, enabling the firm to accelerate discovery and development across its target disease databases.
- Integration into the global biotech ecosystem through LGL offers broader support networks for the company to leverage for its proprietary RNA-based platform, representing a meaningful milestone.
- Lilly Gateway Labs operates as part of a larger corporate structure—alongside Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab—designed to empower biotechnology companies through resource provision.
- Rznomics plans to accelerate candidate discovery across its target gene database comprising over 200 disease targets while establishing global clinical infrastructure and recruiting top-tier R&D researchers in the U.S.
30 Articles
30 Articles
Missoulian
Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics
SEONGNAM, South Korea, Aug. 23, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California.
Rznomics Joins Lilly Gateway Labs to Quicken RNA Therapeutic Candidate Discovery and Development
Rznomics is joining Lilly Gateway Labs (LGL) in San Diego. The company is a clinical-stage biopharmaceutical firm based in South Korea focused on developing RNA-based gene therapies. Lilly Gateway Labs is an innovation hub designed to help biotechnology companies advance groundbreaking science by providing access to wet lab facilities and opportunities to engage with Lilly scientists and executives. Lilly Gateway Labs is part of Lilly Catalyze36…
Rznomics joins Lilly Gateway Labs to advance RNA therapy research
SEONGNAM, South Korea, Aug. 24, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California. Lilly Gateway Labs is a best-in-class innovation hub designed to empower biotechnology companies to advance groundbreaking science by providing access to wet lab facilities and opportunities to en…
Coverage Details
Bias Distribution
- 92% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
